R1 RCM (NASDAQ:RCM) Shares Gap Up to $12.45

R1 RCM Inc. (NASDAQ:RCM)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $12.45, but opened at $13.20. R1 RCM shares last traded at $13.16, with a volume of 2,070,294 shares changing hands.

Analyst Ratings Changes

Several equities analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of R1 RCM in a research report on Wednesday, April 10th. KeyCorp reaffirmed a “sector weight” rating on shares of R1 RCM in a research report on Wednesday, April 10th. Leerink Partnrs reaffirmed an “outperform” rating on shares of R1 RCM in a research report on Monday, February 26th. Guggenheim lowered their target price on R1 RCM from $17.00 to $15.00 and set a “buy” rating for the company in a report on Friday, April 5th. Finally, Barclays reiterated an “equal weight” rating and issued a $14.00 target price on shares of R1 RCM in a report on Wednesday, February 28th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

R1 RCM Stock Down 4.4 %

The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average of $12.84 and a 200 day moving average of $11.46.

R1 RCM (NASDAQ:RCM) last posted its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). R1 RCM had a net margin of 0.15% and a return on equity of 0.12%. The firm had revenue of $603.90 million during the quarter, compared to analysts’ expectations of $612.88 million. R1 RCM’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, research analysts forecast that R1 RCM Inc. will post -0.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other R1 RCM news, President John M. Sparby sold 10,046 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $14.33, for a total transaction of $143,959.18. Following the transaction, the president now owns 265,986 shares in the company, valued at approximately $3,811,579.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 36.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On R1 RCM

Hedge funds have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new stake in shares of R1 RCM during the third quarter worth $36,000. ANTIPODES PARTNERS Ltd boosted its holdings in R1 RCM by 429.5% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock valued at $59,000 after acquiring an additional 4,561 shares during the last quarter. Salem Investment Counselors Inc. acquired a new position in R1 RCM in the fourth quarter valued at $61,000. Van ECK Associates Corp boosted its holdings in R1 RCM by 20.5% in the fourth quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock valued at $65,000 after acquiring an additional 1,044 shares during the last quarter. Finally, QRG Capital Management Inc. acquired a new position in R1 RCM in the first quarter valued at $132,000. Institutional investors and hedge funds own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.